Short term everything looks as expected, in-store payments aren't dead yet, and card payments keep on going up because of cash replacement.
Not sure if I am starting to imaging things but this is where I get anxious. Despite the current lockdowns, Tyro is doing well only because of external factors?
Whatever products they release, they don't seem to get traction.
- Alipay only delivered $16mn (0.5%) of transaction volume out of the total $32bn. I don't accept the COVID explanation on low transactions numbers. Chinese New Year is the most significant spending time for Chinese visitors. CNY was pre-lockdown.
- eCommerce, launched in March 2019 and they only have 384 merchants activated (c. 1% of merchant base after 1.5 years). The solution is MPGS white-label. As per the report, this is on par with CBA and a few other products. I expected the cross-sell to be higher, especially as eCommerce is an adjacent product to the base in-store product offer.
- Deposits and lending (banking) released 5 years ago and still only 1% of the revenue?? With margins up to 8%, lending should be the most profitable product. (Compared to in-store payments which has 0.92% reported margin and going down). I expect more in the lending product after 5 years. Or kill banking alltogether because it is not performing and it is a massive distraction from the payments business.
To top it off, on the media releases, there isn't much of notice since 2018. $52mn (54% of CODB) staff costs for not delivering much that contributes to long term growth makes me anxious. Because it is a long term problem I am still holding, not sure for how much more patience I can muster.
- Forums
- ASX - By Stock
- TYR
- Research from Goldman Sachs
TYR
tyro payments limited
Add to My Watchlist
2.30%
!
89.0¢

Research from Goldman Sachs, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
89.0¢ |
Change
0.020(2.30%) |
Mkt cap ! $470.2M |
Open | High | Low | Value | Volume |
87.0¢ | 89.8¢ | 87.0¢ | $935.9K | 1.054M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 677 | 88.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
89.5¢ | 18912 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 677 | 0.885 |
5 | 34093 | 0.880 |
1 | 11730 | 0.875 |
1 | 3000 | 0.870 |
1 | 3488 | 0.860 |
Price($) | Vol. | No. |
---|---|---|
0.895 | 18912 | 4 |
0.900 | 38376 | 7 |
0.905 | 4000 | 1 |
0.910 | 143900 | 4 |
0.915 | 20000 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
TYR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online